By Fineline Cube 
AbbVie Inc. (NYSE: ABBV) announced positive topline results from the Phase 3 AFFIRM study evaluating risankizumab (SKYRIZI) subcutaneous induction therapy in adult patients with moderately to severely active Crohn’s disease (CD). The study demonstrated statistically significant superiority over placebo on both co‑primary endpoints, reinforcing SKYRIZI’s position in the inflammatory bowel disease (IBD) market.
AFFIRM Study Results
| Endpoint | SKYRIZI SC (Week 12) | Placebo (Week 12) | Statistical Significance | Clinical Impact |
|---|---|---|---|---|
| CDAI Clinical Remission | 55% | 30% | p<0.0001 | 25 percentage‑point absolute benefit |
| Endoscopic Response | 44% | 14% | p<0.0001 | 30 percentage‑point absolute benefit |
Maintenance Phase (Week 24):
- Among week‑12 clinical responders continuing treatment: 67% achieved CDAI clinical remission
- 57% achieved endoscopic response at week 24
Study Design: Phase 3, randomized, double‑blind, placebo‑controlled; subcutaneous induction dosing
Safety Profile
| Parameter | Finding |
|---|---|
| Observation Period | 12‑week double‑blind placebo‑controlled phase |
| Safety Consistency | Aligned with established SKYRIZI Crohn’s disease profile |
| New Safety Risks | None identified |
| Discontinuation Rates | Comparable to placebo arm |
Product Profile & Market Position
Mechanism:
- IL‑23 Selective Inhibition: Blocks p19 subunit of interleukin‑23, a key cytokine in inflammatory signaling
- Differentiation: Targeted immunomodulation vs. broad immunosuppression
Current Approvals:
| Region | Approved Indications |
|---|---|
| U.S. (FDA) | Plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis |
| EU (EMA) | Plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis |
| China (NMPA) | Crohn’s disease, ulcerative colitis |
Commercial & Competitive Analysis
| Factor | Strategic Implication |
|---|---|
| Market Expansion | AFFIRM data supports potential label expansion for SC maintenance dosing optimization |
| Competitive Positioning | Strengthens case vs. ustekinumab (Stelara) and vedolizumab (Entyvio) in bio‑naïve and bio‑experienced segments |
| Formulation Advantage | Subcutaneous delivery offers convenience vs. IV induction alternatives |
| Revenue Contribution | SKYRIZI generated $11.6 billion global sales in 2024; Crohn’s indication contributes ~15% of volume with growth trajectory |
- Pipeline Synergy: Data readout supports ongoing ** ulcerative colitis maintenance studies** and potential combination therapy investigations with ABBV‑3373 (anti‑TNF/TL1A bispecific)
- Pricing Power: Superior endoscopic response rates (44% vs. competitor range 25–35%) support premium positioning in payor negotiations
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory submissions, label expansion, and commercial projections for SKYRIZI in Crohn’s disease. Actual results may differ due to FDA/EMA review timelines, competitive market dynamics, and reimbursement decisions.-Fineline Info & Tech